Literature DB >> 12271128

Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin.

Christiana DelloRusso1, Jeannine M Scott, Dennis Hartigan-O'Connor, Giovanni Salvatori, Catherine Barjot, Ann S Robinson, Robert W Crawford, Susan V Brooks, Jeffrey S Chamberlain.   

Abstract

Duchenne muscular dystrophy is a lethal X-linked recessive disorder caused by mutations in the dystrophin gene. Delivery of functionally effective levels of dystrophin to immunocompetent, adult mdx (dystrophin-deficient) mice has been challenging because of the size of the gene, immune responses against viral vectors, and inefficient infection of mature muscle. Here we show that high titer stocks of three different gutted adenoviral vectors carrying full-length, muscle-specific, dystrophin expression cassettes are able to efficiently transduce muscles of 1-yr-old mdx mice. Single i.m. injections of viral vector restored dystrophin production to 25-30% of mouse limb muscle 1 mo after injection. Furthermore, functional tests of virally transduced muscles revealed almost 40% correction of their high susceptibility to contraction-induced injury. Our results show that functional abnormalities of dystrophic muscle can be corrected by delivery of full-length dystrophin to adult, immunocompetent mdx mice, raising the prospects for gene therapy of muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271128      PMCID: PMC130572          DOI: 10.1073/pnas.202300099

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector.

Authors:  J P Greelish; L T Su; E B Lankford; J M Burkman; H Chen; S K Konig; I M Mercier; P R Desjardins; M A Mitchell; X G Zheng; J Leferovich; G P Gao; R J Balice-Gordon; J M Wilson; H H Stedman
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

2.  DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle.

Authors:  H H Chen; L M Mack; S Y Choi; M Ontell; S Kochanek; P R Clemens
Journal:  Hum Gene Ther       Date:  1999-02-10       Impact factor: 5.695

3.  High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.

Authors:  N Morral; R J Parks; H Zhou; C Langston; G Schiedner; J Quinones; F L Graham; S Kochanek; A L Beaudet
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

4.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

Authors:  G Schiedner; N Morral; R J Parks; Y Wu; S C Koopmans; C Langston; F L Graham; A L Beaudet; S Kochanek
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

5.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.

Authors:  S Kochanek; P R Clemens; K Mitani; H H Chen; S Chan; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

6.  Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene.

Authors:  N Deconinck; T Ragot; G Maréchal; M Perricaudet; J M Gillis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

7.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer.

Authors:  G Acsadi; H Lochmüller; A Jani; J Huard; B Massie; S Prescott; M Simoneau; B J Petrof; G Karpati
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

8.  Persistence in muscle of an adenoviral vector that lacks all viral genes.

Authors:  H H Chen; L M Mack; R Kelly; M Ontell; S Kochanek; P R Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

9.  Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice.

Authors:  S V Brooks
Journal:  J Muscle Res Cell Motil       Date:  1998-02       Impact factor: 2.698

10.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells.

Authors:  R Kumar-Singh; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

View more
  38 in total

1.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Soluble miniagrin enhances contractile function of engineered skeletal muscle.

Authors:  Weining Bian; Nenad Bursac
Journal:  FASEB J       Date:  2011-11-10       Impact factor: 5.191

3.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

Review 4.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

5.  Gene therapy in sport.

Authors:  R J Trent; I E Alexander
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

Review 6.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

Review 7.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

8.  Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.

Authors:  Dejia Li; Akshay Bareja; Luke Judge; Yongping Yue; Yi Lai; Rebecca Fairclough; Kay E Davies; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  J Cell Sci       Date:  2010-05-18       Impact factor: 5.285

Review 9.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

10.  Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression.

Authors:  En Kimura; Sheng Li; Paul Gregorevic; Brent M Fall; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.